Brad has been with Amgen, a biotechnology company headquartered in Thousand Oaks, Ca, since 1999. At Amgen, Brad works in the Licensing Department, which is a business development function responsible for identifying and partnering new therapeutic products and technologies to compliment Amgen’s internal research, development and commercial portfolio. Brad heads the teams responsible for identifying new therapeutic partnering opportunities, which are primarily focused on the areas of oncology, inflammation, neurodegenerative disorders, metabolic disorders and nephrology. Prior to joining Amgen, Brad spent 17 years with Atlantic Richfield Corporation where he worked in a number of strategic planning and business development roles that included mergers and acquisitions and the establishment of foreign joint ventures. Brad received his MBA from the University of California Los Angeles and his BA in from the University of Texas at Austin.